BioStem Technologies, Inc. (OTCMKTS:BSEM – Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 137,800 shares, an increase of 17.1% from the November 30th total of 117,700 shares. Based on an average daily trading volume, of 120,600 shares, the short-interest ratio is currently 1.1 days.
BioStem Technologies Stock Down 1.4 %
BSEM traded down $0.17 during midday trading on Friday, reaching $12.65. The company had a trading volume of 24,767 shares, compared to its average volume of 38,335. The business has a 50-day moving average of $15.84 and a two-hundred day moving average of $12.06. BioStem Technologies has a 1 year low of $4.41 and a 1 year high of $28.26. The company has a market cap of $210.28 million, a P/E ratio of 18.60 and a beta of -0.62.
BioStem Technologies (OTCMKTS:BSEM – Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.01. The firm had revenue of $82.56 million during the quarter, compared to analysts’ expectations of $78.22 million. On average, equities research analysts predict that BioStem Technologies will post 1.41 EPS for the current year.
About BioStem Technologies
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Further Reading
- Five stocks we like better than BioStem Technologies
- The 3 Best Fintech Stocks to Buy Now
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- These 3 Quirky ETFs May Be Strong Plays in 2025
- Breakout Stocks: What They Are and How to Identify Them
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for BioStem Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioStem Technologies and related companies with MarketBeat.com's FREE daily email newsletter.